Cited by 353Pharmaceutical studies and practicesPharmacogenetics and Drug MetabolismAnimal testing and alternatives

The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.

A Novel Strategy for Physiologically Based Predictions of Human Pharmacokinetics

Jones, Hannah M, Parrott, Neil, Jorga, Karin, Lav??, Thierry·2006·Clinical Pharmacokinetics

DOI 10.2165/00003088-200645050-00006

Open this paper in CoChat — free account

Abstract

Background The major aim of this study was to develop a strategy for predicting human pharmacokinetics using physiologically based pharmacokinetic (PBPK) modelling. This was compared with allometry (of plasma concentration-time profiles using the Dedrick approach), in order to determine the best approaches and strategies for the prediction of human pharmacokinetics.Methods PBPK and Dedrick predictions were made for 19 F. Hoffmann-La Roche compounds. A strategy for the prediction of human pharmacokinetics using PBPK modelling was proposed in this study. Predicted values (pharmacokinetic parameters, plasma concentrations) were compared with observed values obtained after intravenous and oral administration in order to assess the accuracy of the prediction methods.Results By following the proposed strategy for PBPK, a prediction would have been made prospectively for approximately 70% of the compounds. The prediction accuracy for these compounds in terms of the percentage of compounds with an average-fold error of <2-fold was 83%, 50%, 75%, 67%, 92% and 100% for apparent oral clearance (CL/F), apparent volume of distribution during terminal phase after oral administration (V(z)/F), terminal elimination half-life (t(1/2)), peak plasma concentration (C(max)), area under the plasma concentration-time curve (AUC) and time to reach C(max) (t(max)), respectively. For the other 30% compounds, unacceptable prediction accuracy was obtained in animals; therefore, a prospective prediction of human pharmacokinetics would not have been made using PBPK. For these compounds, prediction accuracy was also poor using the Dedrick approach. In the majority of cases, PBPK gave more accurate predictions of pharmacokinetic parameters and plasma concentration-time profiles than the Dedrick approach.Conclusions Based on the dataset evaluated in this study, PBPK gave reasonable predictions of human pharmacokinetics using preclinical data and is the recommended approach in the majority of cases. In addition, PBPK modelling is a useful tool to gain insights into the properties of a compound. Thus, PBPK can guide experimental efforts to obtain the relevant information necessary to understand the compound's properties before entry into human, ultimately resulting in a higher level of prediction accuracy.

Integrity signals

Registry

Crossref · 10.2165/00003088-200645050-00006

Cites

76 of 76 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Physiological Parameter Values for Physiologically Based Pharmacokinetic Models
Brown, R. P., Delp, M. D., Lindstedt, S. L., Rhomberg, L. R., & Beliles, R. P. (1997) · Toxicology and Industrial Health · doi:10.1177/074823379701300401 · Cited by 1,408
Physicochemical High Throughput Screening: Parallel Artificial Membrane Permeation Assay in the Description of Passive Absorption Processes
Kansy, M., Senner, F., & Gubernator, K. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm970530e · Cited by 1,304
Prediction of Human Clearance of Twenty-Nine Drugs from Hepatic Microsomal Intrinsic Clearance Data: An Examination of In Vitro Half-Life Approach and Nonspecific Binding to Microsomes
Obach, R. S. (1999) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)14938-0 · Cited by 1,232
The Prediction of Human Pharmacokinetic Parameters from Preclinical and in Vitro Metabolism Data
Obach, R. S., Baxter, J. G., Liston, T. E., Silber, B. M., Jones, B. C., Macintyre, F., Rance, D. J., & Wastall, P. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36999-x · Cited by 987
Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance
Brian Houston, J. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90520-7 · Cited by 925
Characterization of Interintestinal and Intraintestinal Variations in Human CYP3A-Dependent Metabolism
Paine, M. F., Khalighi, M., Fisher, J. M., Shen, D. D., Kunze, K. L., Marsh, C. L., Perkins, J. D., & Thummel, K. E. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37149-6 · Cited by 790
Physiologically Based Pharmacokinetic Modeling 1: Predicting the Tissue Distribution of Moderate-to-Strong Bases
Rodgers, T., Leahy, D., & Rowland, M. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20322 · Cited by 776
The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data
Sun, K. (2005) · Chinese New Drugs Journal · Cited by 762
Predicting the Impact of Physiological and Biochemical Processes on Oral Drug Bioavailability
Agoram, B., Woltosz, W. S., & Bolger, M. B. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00179-x · Cited by 651
Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics
Boxenbaum, H. (1982) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01062336 · Cited by 648 · cited 4×
“[5,25,45] In contrast, allometric scaling has long been the dominant method for interspecies’ scaling;[2,3,6,7] however, owing to its empirical nature and its failure to account for differences in pharmacokinetics across 0.”
BackgroundMethodInfluential

Show all 76 references

Research works printed but not linked: 11

Bernareggi, 1991, J Pharm Sci, 19, 21
Dedrick, 1970, Cancer Chemother Rep, 54, 95
Yokogawa, 1990, Drug Metab Dispos, 18, 258
Carlile, 1997, Drug Metab Dispos, 25, 903
Naritomi, 2001, Drug Metab Dispos, 29, 1316
Lin, 1998, Drug Metab Dispos, 26, 1202
Lave, 1996, J Pharm Sci, 48, 573
Poggesi, 2004, Curr Opin Drug Discov Devel, 7, 100
Paine, 1997, J Pharmacol Exp Ther, 283, 1552
Obach, 1996, Drug Metab Dispos, 24, 1047
Obach, 1997, Drug Metab Dispos, 25, 1359

Sorted by citations

Mechanism-Based Concepts of Size and Maturity in Pharmacokinetics
Anderson, B. J., & Holford, N. H. G. (2007) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094708 · Cited by 1,158
Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science
Rowland, M., Peck, C., & Tucker, G. (2011) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100540 · Cited by 662
Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development
Jones, H., & Rowland‐Yeo, K. (2013) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1038/psp.2013.41 · Cited by 626
Self-citation
To Scale or Not to Scale: The Principles of Dose Extrapolation
Sharma, V., & McNeill, J. H. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00267.x · Cited by 544
The Simcyp ® Population-based ADME Simulator
Jamei, M., Marciniak, S., Feng, K., Barnett, A., Tucker, G., & Rostami-Hodjegan, A. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250802691074 · Cited by 533
Physiologically based pharmacokinetic modeling in drug discovery and development: A pharmaceutical industry perspective
Jones, H., Chen, Y., Gibson, C., Heimbach, T., Parrott, N., Peters, S., Snoeys, J., Upreti, V., Zheng, M., & Hall, S. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.37 · Cited by 488
Self-citation
Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model
Kuepfer, L., Niederalt, C., Wendl, T., Schlender, J., Willmann, S., Lippert, J., Block, M., Eissing, T., & Teutonico, D. (2016) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12134 · Cited by 425
Mechanistic Approaches to Volume of Distribution Predictions: Understanding the Processes
Rodgers, T., & Rowland, M. (2007) · Pharmaceutical Research · doi:10.1007/s11095-006-9210-3 · Cited by 420
PBPK modeling and simulation in drug research and development
Zhuang, X., & Lu, C. (2016) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.04.004 · Cited by 411
Physiologically Based Pharmacokinetic Modeling to Predict Transporter-Mediated Clearance and Distribution of Pravastatin in Humans
Watanabe, T., Kusuhara, H., Maeda, K., Shitara, Y., & Sugiyama, Y. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.146647 · Cited by 351
Pharmacokinetics
Fan, J., & de Lannoy, I. A. M. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.09.007 · Cited by 309
Prediction of Human Pharmacokinetics from Preclinical Information: Comparative Accuracy of Quantitative Prediction Approaches
Hosea, N. A., Collard, W. T., Cole, S., Maurer, T. S., Fang, R. X., Jones, H., Kakar, S. M., Nakai, Y., Smith, B. J., Webster, R., et al. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009333209 · Cited by 300
Self-citation
Prediction of Drug-Drug Interactions with Bupropion and Its Metabolites as CYP2D6 Inhibitors Using a Physiologically-Based Pharmacokinetic Model
Xue, C., Zhang, X., & Cai, W. (2017) · Pharmaceutics · doi:10.3390/pharmaceutics10010001 · Cited by 291
Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs
De Buck, S. S., Sinha, V. K., Fenu, L. A., Nijsen, M. J., Mackie, C. E., & Gilissen, R. A. H. J. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.015644 · Cited by 256
Mechanistic Pharmacokinetic Modeling for the Prediction of Transporter-Mediated Disposition in Humans from Sandwich Culture Human Hepatocyte Data
Jones, H. M., Barton, H. A., Lai, Y., Bi, Y., Kimoto, E., Kempshall, S., Tate, S. C., El‐Kattan, A. F., Houston, J. B., Galetin, A., et al. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.042994 · Cited by 245
Self-citation
Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs
Ieiri, I., Higuchi, S., & Sugiyama, Y. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250902976854 · Cited by 211
Modelling and PBPK Simulation in Drug Discovery
Jones, H. M., Gardner, I. B., & Watson, K. J. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9088-1 · Cited by 213
Self-citation
Safety evaluation of superabsorbent baby diapers
Kosemund, K., Schlatter, H., Ochsenhirt, J. L., Krause, E. L., Marsman, D. S., & Erasala, G. N. (2008) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2008.10.005 · Cited by 196
Whole-body physiologically based pharmacokinetic models
Nestorov, I. A. (2007) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.3.2.235 · Cited by 188
Human Ontogeny of Drug Transporters: Review and Recommendations of the Pediatric Transporter Working Group
Brouwer, K. L. R., Aleksunes, L. M., Brandys, B., Giacoia, G. P., Knipp, G. T., Lukacova, V., Meibohm, B., Nigám, S. K., Rieder, M. J., de Wildt, S. N., et al. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.176 · Cited by 190
Non-invasive Systemic Drug Delivery: Developability Considerations for Alternate Routes of Administration
Mathias, N. R., & Hussain, M. A. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21793 · Cited by 195
PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: Prediction of plasma concentration–time profiles in human by using the physiologically‐based pharmacokinetic modeling approach
Poulin, P., Jones, R. D. O., Jones, H. M., Gibson, C. R., Rowland, M., Chien, J. Y., Ring, B. J., Adkison, K. K., Ku, M. S., He, H., et al. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22550 · Cited by 174
Self-citation
Predicting Oral Drug Absorption: Mini Review on Physiologically-Based Pharmacokinetic Models
Lin, L., & Wong, H. (2017) · Pharmaceutics · doi:10.3390/pharmaceutics9040041 · Cited by 180
Towards Prediction of In Vivo Intestinal Absorption Using a 96-Well Caco-2 Assay
Skolnik, S. M., Lin, X., Wang, J., Chen, X.-H., He, T., & Zhang, B. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22080 · Cited by 154
Food Effects on Oral Drug Absorption: Application of Physiologically-Based Pharmacokinetic Modeling as a Predictive Tool
Cheng, L., & Wong, H. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12070672 · Cited by 160
Whole body physiologically-based pharmacokinetic models: their use in clinical drug development
Edginton, A. N., Theil, F., Schmitt, W., & Willmann, S. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.9.1143 · Cited by 159
Predicting Pharmacokinetics of Drugs Using Physiologically Based Modeling—Application to Food Effects
Parrott, N. J., Lukacova, V., Fraczkiewicz, G., & Bolger, M. B. (2009) · The AAPS Journal · doi:10.1208/s12248-008-9079-7 · Cited by 150
Self-citation
PBTK modelling platforms and parameter estimation tools to enable animal-free risk assessment
Bessems, J. G. M., Loizou, G. D., Krishnan, K., M.A., H. J. C. I., Bernasconi, C., Bois, F. Y., Coecke, S., Collnot, E.-M., Diembeck, W., Farcal, L. R., et al. (2013) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2013.11.008 · Cited by 161
Predicting Pharmacokinetic Food Effects Using Biorelevant Solubility Media and Physiologically Based Modelling
Jones, H. M., Parrott, N. J., Ohlenbusch, G., & Lav, T. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645120-00006 · Cited by 150
Self-citation
Evaluation of a Generic Physiologically Based Pharmacokinetic Model for Lineshape Analysis
Peters, S. A. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847040-00004 · Cited by 150
Physiologically Based Pharmacokinetic Modelling for First-In-Human Predictions: An Updated Model Building Strategy Illustrated with Challenging Industry Case Studies
Miller, N. A., Reddy, M. B., Heikkinen, A. T., Lukacova, V., & Parrott, N. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00741-9 · Cited by 142
Self-citation
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: Comparative assessment of prediction methods of human volume of distribution
Jones, R. D. O., Jones, H. M., Rowland, M., Gibson, C. R., Yates, J. W. T., Chien, J. Y., Ring, B. J., Adkison, K. K., Ku, M. S., He, H., et al. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22553 · Cited by 142
Self-citation
Dosing in Children: A Critical Review of the Pharmacokinetic Allometric Scaling and Modelling Approaches in Paediatric Drug Development and Clinical Settings
Mahmood, I. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-014-0134-5 · Cited by 143
Applications of Human Pharmacokinetic Prediction in First-in-Human Dose Estimation
Zou, P., Yu, Y., Zheng, N., Yang, Y., Paholak, H. J., Yu, L. X., & Sun, D. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9332-y · Cited by 138
Physiologically based pharmacokinetics (PBPK)
Espié, P., Tytgat, D., Sargentini-Maier, M.-L., Poggesi, I., & Watelet, J. (2009) · Drug Metabolism Reviews · doi:10.1080/10837450902891360 · Cited by 140
Toward Predictive Models for Drug-Induced Liver Injury in Humans: Are we There Yet?
Chen, M., Bişğin, H., Tong, L., Hong, H., Fang, H., Borlak, J. T., & Tong, W. (2014) · Biomarkers in Medicine · doi:10.2217/bmm.13.146 · Cited by 136
Utility of Physiologically Based Absorption Modeling in Implementing Quality by Design in Drug Development
Zhang, X., Lionberger, R. A., Davit, B. M., & Yu, L. X. (2011) · The AAPS Journal · doi:10.1208/s12248-010-9250-9 · Cited by 129
Introduction to computational oral absorption simulation
Sugano, K. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250902835506 · Cited by 130
Lipophilicity and biomimetic properties measured by HPLC to support drug discovery
Valko, K. L. (2016) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2016.04.009 · Cited by 129
Applications of Physiologically Based Absorption Models in Drug Discovery and Development
Parrott, N. J., & Lavé, T. (2008) · Molecular Pharmaceutics · doi:10.1021/mp8000155 · Cited by 124
Self-citation
Advancing Predictions of Tissue and Intracellular Drug Concentrations Using In Vitro, Imaging and Physiologically Based Pharmacokinetic Modeling Approaches
Guo, Y., Chu, X., Parrott, N. J., Brouwer, K. L. R., Hsu, V., Nagar, S., Matsson, P., Sharma, P. K., Snoeys, J., Sugiyama, Y., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1183 · Cited by 122
Self-citation
Challenges and opportunities with modelling and simulation in drug discovery and drug development
Lavé, T., Parrott, N., Grimm, H. P., Fleury, A., & Reddy, M. (2007) · Xenobiotica · doi:10.1080/00498250701534885 · Cited by 115
Self-citation
Development of a Physiologically Based Model for Oseltamivir and Simulation of Pharmacokinetics in Neonates and Infants
Parrott, N. J., Davies, B., Hoffmann, G., Koerner, A., Lavé, T., Prinssen, E. P. M., Theogaraj, E., & Singer, T. (2011) · Clinical Pharmacokinetics · doi:10.2165/11592640-000000000-00000 · Cited by 116
Self-citation
Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies
Chen, Y., Jin, J. Y., Mukadam, S., Malhi, V., & Kenny, J. R. (2012) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1769 · Cited by 113
Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first‐in‐human study
Brossard, P., Derendorf, H., Xu, J., Maatouk, H., Halabi, A., & Dingemanse, J. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12129 · Cited by 111
Cell cultures in drug discovery and development: The need of reliable in vitro-in vivo extrapolation for pharmacodynamics and pharmacokinetics assessment
Jaroch, K., Jaroch, A., & Bojko, B. (2017) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2017.07.023 · Cited by 119
Simulation of Human Intravenous and Oral Pharmacokinetics of 21 Diverse Compounds Using Physiologically Based Pharmacokinetic Modelling
Jones, H. M., Gardner, I. B., Collard, W. T., Stanley, P. J., Oxley, P., Hosea, N. A., Plowchalk, D., Gernhardt, S., Lin, J., Dickins, M., et al. (2011) · Clinical Pharmacokinetics · doi:10.2165/11539680-000000000-00000 · Cited by 110
Self-citation
Application of physiologically based pharmacokinetic modeling and clearance concept to drugs showing transporter-mediated distribution and clearance in humans
Watanabe, T., Kusuhara, H., & Sugiyama, Y. (2010) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-010-9176-y · Cited by 110
Dissolution and Translational Modeling Strategies Toward Establishing an In Vitro-In Vivo Link—a Workshop Summary Report
Heimbach, T., Suarez‐Sharp, S., Kakhi, M., Holmstock, N., Olivares-Morales, A., Pepin, X. J. H., Sjögren, E., Tsakalozou, E., Seo, P., Li, M., et al. (2019) · The AAPS Journal · doi:10.1208/s12248-019-0298-x · Cited by 110
Dose Selection Based on Physiologically Based Pharmacokinetic (PBPK) Approaches
Jones, H. M., Mayawala, K., & Poulin, P. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9446-2 · Cited by 111
Self-citation
Toward an improved prediction of humanin vivobrain penetration
Summerfield, S. G., Lucas, A. J., Porter, R. A., Jeffrey, P., Gunn, R. N., Read, K. R., Stevens, A. J., Metcalf, A., Osuna, M. C., Kilford, P. J., et al. (2008) · Xenobiotica · doi:10.1080/00498250802499459 · Cited by 105
Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs?
Bouzom, F., Ball, K., Perdaems, N., & Walther, B. (2012) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.1767 · Cited by 104
Application of PBPK modelling in drug discovery and development at Pfizer
Jones, H. M., Dickins, M., Youdim, K. A., Gosset, J. R., Attkins, N., Hay, T. L., Gurrell, I. K., Logan, Y. R., Bungay, P. J., Jones, B., et al. (2011) · Xenobiotica · doi:10.3109/00498254.2011.627477 · Cited by 100
Self-citation
The pig as a preclinical model for predicting oral bioavailability and in vivo performance of pharmaceutical oral dosage forms: a PEARRL review
Henze, L. J., Koehl, N. J., O’Shea, J. P., Kostewicz, E. S., Holm, R., & Griffin, B. T. (2018) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12912 · Cited by 99
A Physiologically Based Pharmacokinetic Model of the Minipig: Data Compilation and Model Implementation
Suenderhauf, C., & Parrott, N. J. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0911-5 · Cited by 95
Self-citation
The Prediction of Drug Metabolism, Tissue Distribution, and Bioavailability of 50 Structurally Diverse Compounds in Rat Using Mechanism-Based Absorption, Distribution, and Metabolism Prediction Tools
Buck, S. S. D., Sinha, V. K., Fenu, L. A., Gilissen, R., Mackie, C. E., & Nijsen, M. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.014027 · Cited by 92
Prediction of drug–drug interaction potential using physiologically based pharmacokinetic modeling
Min, J. S., & Bae, S. K. (2017) · Archives of Pharmacal Research · doi:10.1007/s12272-017-0976-0 · Cited by 88
Quantitative structure–pharmacokinetic/pharmacodynamic relationships
Mager, D. E. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.08.002 · Cited by 87
On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development
Lowe, P. J., Hijazi, Y., Luttringer, O., Yin, H., Sarangapani, R., & Howard, D. (2007) · Xenobiotica · doi:10.1080/00498250701648008 · Cited by 82
Prediction of pharmacokinetic profile of valsartan in human based on in vitro uptake transport data
Poirier, A., Cascais, A., Funk, C., & Lavé, T. (2009) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-009-9139-3 · Cited by 80
Self-citation
Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates – An evaluation and case study using GastroPlus™
Heikkinen, A. T., Baneyx, G., Caruso, A., & Parrott, N. (2012) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.06.013 · Cited by 76
Self-citation
A “middle-out” approach to human pharmacokinetic predictions for OATP substrates using physiologically-based pharmacokinetic modeling
Li, R., Barton, H. A., Yates, P. D., Ghosh, A., Wolford, A. C., Riccardi, K. A., & Maurer, T. S. (2014) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-014-9357-1 · Cited by 75
Physiologically based pharmacokinetic modeling of CYP3A4 induction by rifampicin in human: Influence of time between substrate and inducer administration
Baneyx, G., Parrott, N. J., Meille, C., Iliadis, A., & Lavé, T. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.02.002 · Cited by 79
Self-citation
Developing Exposure/Response Models for Anticancer Drug Treatment: Special Considerations
Mould, D., Walz, A., Lavé, T., Gibbs, J., & Frame, B. (2015) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.16 · Cited by 75
Self-citation
Development of a Web-Based Toolbox to Support Quantitative In-Vitro-to-In-Vivo Extrapolations (QIVIVE) within Nonanimal Testing Strategies
Punt, A., Pinckaers, N. E. T., Peijnenburg, A., & Louisse, J. (2020) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.0c00307 · Cited by 73
Preclinical Prediction of Human Brain Target Site Concentrations: Considerations in Extrapolating to the Clinical Setting
Westerhout, J., Danhof, M., & de Lange, E. C. M. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22604 · Cited by 72
Physiologically-based Kinetic Modelling (PBK Modelling): Meeting the 3Rs Agenda
d’Yvoire, M. B., Prieto, P., Blaauboer, B. J., Bois, F. Y., Boobis, A. R., Brochot, C., Coecke, S., Freidig, A. P., Gundert‐Remy, U., Härtung, T., et al. (2007) · Alternatives to Laboratory Animals · doi:10.1177/026119290703500606 · Cited by 72
Self-citation
Pharmacometrics at FDA: Evolution and Impact on Decisions
Powell, J. R., & Gobburu, J. V. S. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100234 · Cited by 72
Prediction of Crizotinib-Midazolam Interaction Using the Simcyp Population-Based Simulator: Comparison of CYP3A Time-Dependent Inhibition between Human Liver Microsomes versus Hepatocytes
Mao, J., Johnson, T. R., Shen, Z., & Yamazaki, S. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.049114 · Cited by 71
Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling
Li, G., Wang, K., Chen, R., Hao-ru, Z., Yang, J., & Zheng, Q. (2012) · Acta Pharmacologica Sinica · doi:10.1038/aps.2012.103 · Cited by 70
Influence of different proton pump inhibitors on the pharmacokinetics of voriconazole
Qi, F., Zhu, L., Li, N., Ge, T., Xu, G., & Liao, S. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.11.025 · Cited by 69
Lumping of physiologically-based pharmacokinetic models and a mechanistic derivation of classical compartmental models
Pilari, S., & Huisinga, W. (2010) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-010-9165-1 · Cited by 67
Physiologically Based Predictions of the Impact of Inhibition of Intestinal and Hepatic Metabolism on Human Pharmacokinetics of CYP3A Substrates
Fenneteau, F., Poulin, P., & Nekka, F. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21802 · Cited by 66
Predicting Pharmacokinetic Profiles Using in Silico Derived Parameters
Hosea, N. A., & Jones, H. M. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300482w · Cited by 65
Self-citation
Predictions of Metabolic Drug-Drug Interactions Using Physiologically Based Modelling
Perdaems, N., Blasco, H., Vinson, C., Chenel, M., Whalley, S., Cazade, F., & Bouzom, F. (2010) · Clinical Pharmacokinetics · doi:10.2165/11318130-000000000-00000 · Cited by 59
PhRMA CPCDC Initiative on Predictive Models of Human Pharmacokinetics, Part 1: Goals, Properties of the Phrma Dataset, and Comparison with Literature Datasets
Poulin, P., Jones, H. M., Jones, R. D. O., Yates, J. W. T., Gibson, C. R., Chien, J. Y., Ring, B. J., Adkison, K. K., He, H., Vuppugalla, R., et al. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22554 · Cited by 62
Self-citation
A testing strategy to predict risk for drug-induced liver injury in humans using high-content screen assays and the ‘rule-of-two’ model
Chen, M., Tung, C.-W., Shi, Q., Guo, L., Shi, L. M., Fang, H., Borlak, J. T., & Tong, W. (2014) · Archives of Toxicology · doi:10.1007/s00204-014-1276-9 · Cited by 62
PBPK Modeling of Intestinal and Liver Enzymes and Transporters in Drug Absorption and Sequential Metabolism
Fan, J., Chen, S., Chow, E. C. Y., & Pang, K. S. (2010) · Current Drug Metabolism · doi:10.2174/138920010794328931 · Cited by 63
Prediction of Oral Pharmacokinetics of cMet Kinase Inhibitors in Humans: Physiologically Based Pharmacokinetic Model Versus Traditional One-Compartment Model
Yamazaki, S., Skaptason, J., Romero, D., Vekich, S., Jones, H. M., Tan, W., Wilner, K. D., & Koudriakova, T. B. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.035857 · Cited by 62
Self-citation
Mechanistic Modeling of Hepatic Transport from Cells to Whole Body: Application to Napsagatran and Fexofenadine
Poirier, A., Funk, C., Scherrmann, J., & Lavé, T. (2009) · Molecular Pharmaceutics · doi:10.1021/mp8002495 · Cited by 61
Self-citation
Gut Wall Metabolism. Application of Pre-Clinical Models for the Prediction of Human Drug Absorption and First-Pass Elimination
Jones, C. R., Hatley, O. J. D., Ungell, A.-L. B., Hilgendorf, C., Peters, S. A., & Rostami‐Hodjegan, A. (2016) · The AAPS Journal · doi:10.1208/s12248-016-9889-y · Cited by 66
Evaluation of the Success of High-Throughput Physiologically Based Pharmacokinetic (HT-PBPK) Modeling Predictions to Inform Early Drug Discovery
Naga, D., Parrott, N. J., Ecker, G. F., & Olivares‐Morales, A. (2022) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00040 · Cited by 62
Self-citation
Pre-clinical pharmacokinetics of UK-453,061, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), and use of in silico physiologically based prediction tools to predict the oral pharmacokinetics of UK-453,061 in man
Allan, G. A., Davis, J. D., Dickins, M., Gardner, I., Jenkins, T. M., Jones, H. M., Webster, R., & Westgate, H. (2008) · Xenobiotica · doi:10.1080/00498250802069088 · Cited by 60
Self-citation
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: Prediction of plasma concentration–time profiles in human from in vivo preclinical data by using the Wajima approach
Vuppugalla, R., Marathe, P., He, H., Jones, R. D. O., Yates, J. W. T., Jones, H. M., Gibson, C. R., Chien, J. Y., Ring, B. J., Adkison, K. K., et al. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22551 · Cited by 60
Self-citation
A Physiologically Based Pharmacokinetic Drug–Disease Model to Predict Carvedilol Exposure in Adult and Paediatric Heart Failure Patients by Incorporating Pathophysiological Changes in Hepatic and Renal Blood Flows
Rasool, M. F., Khalil, F., & Läer, S. (2015) · Clinical Pharmacokinetics · doi:10.1007/s40262-015-0253-7 · Cited by 59
Physiologically based approaches towards the prediction of pharmacokinetics:in vitro–in vivoextrapolation
Buck, S. S. D., & Mackie, C. E. (2007) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.3.6.865 · Cited by 59
Role of transport proteins in drug discovery and development: a pharmaceutical perspective
Ayrton, A. D., & Morgan, P. (2008) · Xenobiotica · doi:10.1080/00498250801923855 · Cited by 58
Quantitative ADME Proteomics – CYP and UGT Enzymes in the Beagle Dog Liver and Intestine
Heikkinen, A. T., Friedlein, A., Matondo, M., Hatley, O. J. D., Petsalo, A., Juvonen, R. O., Galetin, A., Rostami‐Hodjegan, A., Aebersold, R. H., Lamerz, J., et al. (2014) · Pharmaceutical Research · doi:10.1007/s11095-014-1446-8 · Cited by 58
Self-citation
Pharmacokinetic predictions in children by using the physiologically based pharmacokinetic modelling
Bouzom, F., & Walther, B. (2008) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2008.00648.x · Cited by 55
Prediction of Drug Tissue to Plasma Concentration Ratios Using a Measured Volume of Distribution in Combination With Lipophilicity
Jansson‐Löfmark, R., Bredberg, U., & Ashton, M. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21130 · Cited by 53
The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance
Fenner, K. S., Jones, H. M., Ullah, M., Kempshall, S., Dickins, M., Lai, Y., Morgan, P., & Barton, H. A. (2011) · Xenobiotica · doi:10.3109/00498254.2011.626464 · Cited by 54
Self-citation
Human clearance prediction: shifting the paradigm
Lavé, T., Chapman, K. L., Goldsmith, P., & Rowland, M. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250903099649 · Cited by 51
Self-citation
Predicting Oral Clearance in Humans
Sinha, V. K., Buck, S. S. D., Fenu, L. A., Smit, J. W., Nijsen, M., Gilissen, R., Peer, A. V., Lavrijsen, K., & Mackie, C. E. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847010-00004 · Cited by 50
Development of a Unified Dissolution and Precipitation Model and Its Use for the Prediction of Oral Drug Absorption
Jakubiak, P., Wagner, B., Grimm, H. P., Petrig-Schaffland, J., Schuler, F., & Alvarez‐Sánchez, R. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00808 · Cited by 49
Formed and preformed metabolites: facts and comparisons
Pang, K., Morris, M., & Sun, H. (2008) · The Journal of pharmacy and pharmacology · doi:10.1211/jpp.60.10.0001 · Cited by 45
Differences in Food Effects for 2 Weak Bases With Similar BCS Drug-Related Properties: What Is Happening in the Intestinal Lumen?
Cristofoletti, R., Patel, N., & Dressman, J. (2016) · Journal of Pharmacy and Science · doi:10.1016/j.xphs.2015.11.033 · Cited by 46
A Physiologically‐Based Pharmacokinetic Model for the Prediction of Monoclonal Antibody Pharmacokinetics From In Vitro Data
Jones, H. M., Zhang, Z., Jasper, P., Luo, H., Avery, L. B., King, L. E., Neubert, H., Barton, H. A., Betts, A. M., & Webster, R. (2019) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12461 · Cited by 48
Self-citation
Physiologically Based Pharmacokinetic Modeling
M.A., H. J. C. I., Reddy, M. B., Lavé, T., & Andersen, M. E. (2010) · Wiley eBooks · doi:10.1002/9780470571224.pse065 · Cited by 47
Self-citation
Novel in vitro and mathematical models for the prediction of chemical toxicity
Williams, D. P., Shipley, R. J., Ellis, M. J., Webb, S., Ward, J., Gardner, I. B., & Creton, S. K. (2012) · Toxicology Research · doi:10.1039/c2tx20031g · Cited by 47
Physiologically Based Pharmacokinetic Prediction of Telmisartan in Human
Li, R., Ghosh, A., Maurer, T. S., Kimoto, E., & Barton, H. A. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.058461 · Cited by 44

Authors: Jones, H. M., Parrott, N., Jorga, K., & Lav??, T.
Affiliations: F. Hoffmann-La Roche AG (CH)
Corresponding author: Jones, Hannah M
ORCID: Jones, Hannah M
Parrott, Neil
Venue: Clinical Pharmacokinetics
Publisher: Springer Science and Business Media LLC
Published: 2006
Volume: 45
Issue: 5
Pages: 511-542
ISSN: 0312-5963 (ISSN-L)
DOI: 10.2165/00003088-200645050-00006
OpenAlex: W2146393360
Cited by: 352
References: 76
Citations by year: 2026: 10 · 2025: 13 · 2024: 10 · 2023: 13 · 2022: 18 · 2021: 17 · 2020: 16 · 2019: 17 · 2018: 13 · 2017: 14 · 2016: 20 · 2015: 19 · 2014: 19 · 2013: 19 · 2012: 26
FWCI: 20.15
Type: journal article
Language: en
Open access: closed
Locations: Clinical Pharmacokinetics (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
Keywords: physiologically based pharmacokinetic modelling, human pharmacokinetic prediction, allometry, plasma concentration-time curve, oral clearance, volume of distribution, elimination half-life, prediction accuracy, pharmaceutical compounds
MeSH terms: Animals, Pharmaceutical Preparations, Humans, Models, Biological, Pharmacokinetics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A Novel Strategy for Physiologically Based Predictions of Human Pharmacokinetics

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks